Last reviewed 2026-06-10 · How we verify

Gram-Negative Bacterial Infections — Treatment Landscape & Competitive Intelligence

Gram-Negative Bacterial Infections (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Gram-Negative Bacterial Infections, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Shionogi · 1 drug in Gram-Negative Bacterial Infections

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Gram-Negative Bacterial Infections:

• Gram-Negative Bacterial Infections treatment updates — RSS
• Gram-Negative Bacterial Infections treatment updates — Atom
• Gram-Negative Bacterial Infections treatment updates — JSON

Cite this brief

Drug Landscape (2026). Gram-Negative Bacterial Infections — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gram-negative-bacterial-infections. Accessed 2026-06-10.

Related

• Gram-Negative Bacterial Infections full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing